COP, cryptogenic organizing pneumonia; CT, computed tomography; GGO, ground-glass opacities; T-DXd, trastuzumab deruxtecan. Fig 2. COP pattern of pneumonitis in a 76-year-old woman with breast cancer ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 13.9% of the patients who received trastuzumab deruxtecan (grade 1 or 2 in 33 patients and grade 3 in 1) and in 1.3% ...

A higher percentage of patients assigned trastuzumab deruxtecan experienced interstitial lung disease/pneumonitis (15.2% vs. 3.1%); however, cases were mild or moderate, Hurvitz said.

WILMINGTON, Del.--(BUSINESS WIRE)--High-level results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated ...

Trastuzumab deruxtecan belongs to a group of antineoplastic drugs known as antibody-drug conjugates (ADCs). This type of treatment combines two therapies into one.

With a median progression-free survival of more than three years, the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to become a new first-line ...

Get 7 Days Free Sign In Sign In Topics ...

Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma Ninety patients with advanced cancers who ...

With a median progression-free survival of more than three years, the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to become a new first-line ...